000300247 001__ 300247
000300247 005__ 20250821121131.0
000300247 0247_ $$2pmid$$apmid:40181524
000300247 0247_ $$2ISSN$$a0020-7136
000300247 0247_ $$2ISSN$$a1097-0215
000300247 0247_ $$2doi$$a10.1002/ijc.35429
000300247 0247_ $$2altmetric$$aaltmetric:175926991
000300247 037__ $$aDKFZ-2025-00708
000300247 041__ $$aEnglish
000300247 082__ $$a610
000300247 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000300247 245__ $$aImpact of exercise on sexual health, body image, and therapy-related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT trial.
000300247 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000300247 3367_ $$2DRIVER$$aarticle
000300247 3367_ $$2DataCite$$aOutput Types/Journal article
000300247 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1749536952_29236
000300247 3367_ $$2BibTeX$$aARTICLE
000300247 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300247 3367_ $$00$$2EndNote$$aJournal Article
000300247 500__ $$a#EA:C110#LA:C110# / 2025 Aug 1;157(3):490-503
000300247 520__ $$aThe understanding and treatment of sexual health problems, impaired body image, and other non-life threatening but burdensome symptoms of women with metastatic breast cancer (mBC) is still insufficient. We studied the factors associated with such symptoms and investigated whether these problems could be alleviated by a structured exercise intervention. In the multinational PREFERABLE-EFFECT study, 355 women with mBC were randomly assigned to usual care (n = 178) or a 9-month supervised exercise program (n = 177). Breast cancer-specific functions and symptoms (EORTC QLQ-BR42) were assessed at baseline, 3, 6 (primary timepoint), and 9 months. Linear regression models and linear mixed models for repeated measures were calculated. At baseline, participants were 55.4 ± 11.2 years old, 52.4% were undergoing endocrine therapy, and 25.4% chemotherapy. Baseline sexual functioning was low, with 94.3% reporting no or little sexual activity. Age and depressive symptoms were negatively associated with sexual functioning. Among sexually active women, 46.2% felt no or little sexual enjoyment and 37.3% suffered from vaginal dryness. Body image was reported as low by 23.7%. Exercise significantly improved sexual functioning (6-months between-group difference (BGD) = 5.6, 95% CI [1.9, 9.4], effect size (ES) = 0.28) and vaginal symptoms (BGD = -7.1 [-11.7, -2.5], ES = 0.25), compared to usual care. Effects on body image were marginal (BGD = 4.0 [-0.2, 8.3], ES = 0.14). Among participants undergoing chemotherapy (n = 90), exercise reduced chemotherapy side-effects (BGD = -8.2 [-15.4, -1.0], ES = 0.48). In conclusion, women with mBC often experience sexual and vaginal problems and other treatment-related side-effects. A 9-month supervised exercise program vs. control was effective in improving sexual functioning and vaginal symptoms among women with mBC.
000300247 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300247 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000300247 650_7 $$2Other$$aexercise
000300247 650_7 $$2Other$$ametastatic breast cancer
000300247 650_7 $$2Other$$aquality of life
000300247 650_7 $$2Other$$asexual health
000300247 650_7 $$2Other$$asupportive care
000300247 7001_ $$00000-0002-6216-2609$$aHiensch, Anouk E$$b1
000300247 7001_ $$aDepenbusch, Johanna$$b2
000300247 7001_ $$00000-0002-6641-7605$$aMonninkhof, Evelyn M$$b3
000300247 7001_ $$aBelloso, Jon$$b4
000300247 7001_ $$aClauss, Dorothea$$b5
000300247 7001_ $$00009-0008-5847-7086$$aGunasekara, Nadira$$b6
000300247 7001_ $$00000-0002-9078-0180$$aTrevaskis, Mark$$b7
000300247 7001_ $$00000-0002-5617-9076$$aRundqvist, Helene$$b8
000300247 7001_ $$aWiskemann, Joachim$$b9
000300247 7001_ $$aMüller, Jana$$b10
000300247 7001_ $$00000-0003-4892-4061$$aSweegers, Maike G$$b11
000300247 7001_ $$aSchneweiss, Andreas$$b12
000300247 7001_ $$aAltena, Renske$$b13
000300247 7001_ $$aKufel-Grabwska, Joanna$$b14
000300247 7001_ $$aBijlsma, Rhodé M$$b15
000300247 7001_ $$avan Leeuwen-Snoeks, Lobke$$b16
000300247 7001_ $$aHuinink, Daan Ten Bokkel$$b17
000300247 7001_ $$aSonke, Gabe$$b18
000300247 7001_ $$aBrandner, Susanne$$b19
000300247 7001_ $$aSavas, Peter$$b20
000300247 7001_ $$aAntill, Yoland$$b21
000300247 7001_ $$aWhite, Michelle$$b22
000300247 7001_ $$aAncizar, Nerea$$b23
000300247 7001_ $$avan der Wall, Elsken$$b24
000300247 7001_ $$aAaronson, Neil K$$b25
000300247 7001_ $$aSenkus, Elzbieta$$b26
000300247 7001_ $$00000-0003-0359-3641$$aUrruticoechea, Ander$$b27
000300247 7001_ $$00000-0001-6250-0041$$aZopf, Eva M$$b28
000300247 7001_ $$aBloch, Wilhelm$$b29
000300247 7001_ $$00000-0002-7794-7767$$aStuiver, Martijn M$$b30
000300247 7001_ $$00000-0001-8317-7829$$aWengström, Yvonne$$b31
000300247 7001_ $$00000-0003-0643-3790$$aMay, Anne M$$b32
000300247 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b33$$eLast author$$udkfz
000300247 773__ $$0PERI:(DE-600)1474822-8$$aDOI:10.1002/ijc.35429$$n3$$p490-503$$tInternational journal of cancer$$v157$$x0020-7136$$y2025
000300247 909CO $$ooai:inrepo02.dkfz.de:300247$$pVDB
000300247 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000300247 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000300247 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000300247 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000300247 9141_ $$y2025
000300247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300247 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000300247 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300247 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000300247 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000300247 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000300247 980__ $$ajournal
000300247 980__ $$aVDB
000300247 980__ $$aI:(DE-He78)C110-20160331
000300247 980__ $$aUNRESTRICTED